Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Single Dose, Randomised, Cross-over Study to Determine the Fasted State pharmacokinetics of Oxycodone from Oxycodone Tamper Resistant (OTR) Tablet 40 mg and OXYCONTIN Tablet 40 mg in Chinese Subjects with Chronic Pain

Next Previous
Search
Trial Profile

An Open-label, Single Dose, Randomised, Cross-over Study to Determine the Fasted State pharmacokinetics of Oxycodone from Oxycodone Tamper Resistant (OTR) Tablet 40 mg and OXYCONTIN Tablet 40 mg in Chinese Subjects with Chronic Pain

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 Nov 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oxycodone (Primary) ; Naltrexone
  • Indications Pain
  • Focus Pharmacokinetics
  • Sponsors Mundipharma (China) Pharmaceutical

    • Most Recent Events

    • 02 Nov 2019 Status changed from not yet recruiting to completed as per the results published in the Clinical Drug Investigation
    • 02 Nov 2019 Results assessing pharmacokinetics of oxycodone tamper resistant tablet published in the Clinical Drug Investigation
    • 23 Jul 2018 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top